Clinical Trial Update: Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating oral INS018_055 in idiopathic pulmonary fibrosis has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• INS018_055

Snippet

Sponsor: InSilico Medicine Hong Kong Limited | Conditions: Idiopathic Pulmonary Fibrosis (IPF) | Phase 2 | Status: COMPLETED | Results posted: 2025-12-02